Non-lipid-related effects of statins

References

• Corsini A, Bellosta S, Baetta R, Fumagalli R, Bernini F. New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413–28
   PubMed Web of Science ®Google Scholar
• Brown B G, Zhao X Q, Sacco D E, Albers J J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781–91
   PubMed Web of Science ®Google Scholar
• Downs J R, Clearfield M, Weis S, Whitney E, Shapiro D R, Beere P A, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPSTTexCAPS. JAMA 1998; 279: 1615–22
   PubMed Web of Science ®Google Scholar
• Herd J A, Ballantyne C M, Farmer J A, Ferguson J J, III, Jones P H, West, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study (LCAS)). Am J Cardiol 1997; 80: 278–86
   PubMed Web of Science ®Google Scholar
• Jukema J W, Bruschke A VG, van Boven A J, Reiber J H, Bal E T, Zwinderman A H, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth 24. Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–57
   PubMed Web of Science ®Google Scholar
• Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999; 144: 263–70
   PubMed Web of Science ®Google Scholar
• Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s). Lancet 1994; 344: 1383–9
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe S M, Ford I, Isles C G, Lorimer A R, MacFarlane P W, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7
   PubMed Web of Science ®Google Scholar
• Pitt B, Waters D, Brown W V, van Boven A J, Schwartz L, Title L M, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N EnglJ Med 1999; 341: 70–6
   PubMed Web of Science ®Google Scholar
• Hunninghake D B. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992; 3: 22–8
   Google Scholar
• Gotto A M, Jr, Grundy S M. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data. Issues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, Ninth Council meeting. Circulation 1999; 99: E1–E7
   PubMedGoogle Scholar
• Feussner G. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1994; 5: 59–68
   PubMedGoogle Scholar
• Grunler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1994; 1212: 259–77
   PubMed Web of Science ®Google Scholar
• Goldstein J L, Brown M S. Regulation of the mevalonate pathway. Nature 1990; 343: 425–30
   PubMed Web of Science ®Google Scholar
• Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 1993; 104: 19–26
   PubMedGoogle Scholar
• Corsini A, Mazzotti M, Raiteri M, Soma M R, Gabbiani G, Fumagalli R, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117–25
   PubMed Web of Science ®Google Scholar
• Glomset J A, Gelb M H, Farnsworth C C. Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem Sci 1990; 15: 139–42
   PubMed Web of Science ®Google Scholar
• Maltese W A. Post-translational modification of proteins by isoprenoids in mammalian cells. FASEB J 1990; 4: 3319–28
   PubMed Web of Science ®Google Scholar
• Glomset J A, Farnsworth C C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994; 10: 181–205
   PubMedGoogle Scholar
• Ross R. Atherosclerosis—an inflammatory disease. N Engl j Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Wissler R W. Update on the pathogenesis of atherosclerosis. AmJ Med 1991; 91(Suppl 1B)1B-3S–9S
   Google Scholar
• Ip J H, Fuster V, Badimon L, Badimon J, Taubman M B, Chesebro J H. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. j Am Coll Cardiol 1990; 15: 1667–87
   PubMed Web of Science ®Google Scholar
• Richardson P D, Davies M J, Born G VR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941–4
   PubMed Web of Science ®Google Scholar
• Burleigh M C, Briggs A D, Lendon C L, Davies M J, Born G V, Richardson P D. Collagen types I and II, collagen content, GAGS and mechanical strength of human atherosclerotic plaque caps: snap-wise variations. Atherosclerosis 1992; 96: 71–81
   PubMedGoogle Scholar
• Dollery C M, McEwan J R, Henney A M. Matrix metallo-proteinases and cardiovascular disease. Circ Res 1995; 77: 863–8
   PubMed Web of Science ®Google Scholar
• Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1671–8
   PubMed Web of Science ®Google Scholar
• Rosenson R S, Tangney C C. Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998; 279: 1643–50
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witzum J L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–24
   PubMed Web of Science ®Google Scholar
• Laufs U, La Fata V, Plutzky J, Liao J K. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97: 1129–35
   PubMed Web of Science ®Google Scholar
• Diaz M N, Frei B, Vita J A, Keaney J F J. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408–16
   PubMed Web of Science ®Google Scholar
• Bjorkerud B, Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol 1996; 16: 416–24
   PubMedGoogle Scholar
• Broze G J, Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159–69
   PubMed Web of Science ®Google Scholar
• Aviram M, Rosenblat M, Bisgaier C L, Newton R S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271–80
   PubMed Web of Science ®Google Scholar
• Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11–8
   PubMed Web of Science ®Google Scholar
• Kleinveld H A, Demacker P NM, De Haan A FJ, Stalenhoef A FH. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993; 23: 289–95
   PubMedGoogle Scholar
• Hofhnan R, Brook G J, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 1992; 93: 105–13
   PubMedGoogle Scholar
• Giroux L M, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165: 335–8
   PubMed Web of Science ®Google Scholar
• Wagner A H, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61–9
   PubMed Web of Science ®Google Scholar
• Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39–45
   PubMed Web of Science ®Google Scholar
• Suzumura K, Yasuhara M, Tanaka K, Suzuki T. Protective effect of fluvastatin sodium (XU-62–320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 1999; 57: 697–703
   PubMed Web of Science ®Google Scholar
• Umetani N, Kanayama Y, Okamura M, Negoro N, Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta 1996; 1303: 199–206
   PubMedGoogle Scholar
• Hrboticky N, Draude G, Hapfelmeier G, Lorenz R, Weber P C. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during early stage of differentiation into macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 1267–75
   PubMed Web of Science ®Google Scholar
• Pietsch A, Erl W, Lorenz R L. Lovastatin reduces the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996; 52: 433–9
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002–12
   PubMed Web of Science ®Google Scholar
• Forstennann U, Mugge A, Alheid U, Haverich A, Frolich J C. Selective attenuation of endothelium-mediated vaso-dilation in atherosclerotic human coronary arteries. Circ Res 1988; 62: 185–90
   PubMedGoogle Scholar
• Jeserich M, Múnzel T, Just H, Drexier H. Reduced plasma L-arginine in hypercholesterolemia. Lancet 1992; 339: 561
   PubMed Web of Science ®Google Scholar
• Cooke J P, Singer A H, Tsao P, Zera P, Rowan R A, Billingham M E. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J CIin Invest 1992; 90: 1168–72
   PubMed Web of Science ®Google Scholar
• Clarkson P, Adam M R, Powe A J, Donald A E, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J CIin Invest 1996; 97: 1989–94
   PubMed Web of Science ®Google Scholar
• Osborne J A, Lento P H, Siegfried M R, Stahl G L, Fusman B, Lefer A M. Cardiovascular effects of acute hypercholesterolemia in rabbits. J CIin Invest 1989; 83: 465–73
   PubMed Web of Science ®Google Scholar
• Eichstadt H W, Eskotter H, Hoffmann I, Amthauer H W, Weidinger G. Improvement of myocardial perfusion by shortterm fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A–SA
   PubMedGoogle Scholar
• Guethlin M, Kasel A M, Coppenrath K, Ziegler S, Delius W, Schwaiger M. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 1999; 99: 475–81
   PubMedGoogle Scholar
• Baller D, Notohamiprodjo G, Gleichmann U, Holzinger J, Weise R, Lehmann J. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999; 99: 2871–5
   PubMedGoogle Scholar
• O'DriscoU G, Green D, Taylor R R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–31
   PubMedGoogle Scholar
• Williams J K, Sukhova G K, Herrington D M, Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684–91
   PubMed Web of Science ®Google Scholar
• Laufs U, La Fata V, Liao J K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725–9
   PubMed Web of Science ®Google Scholar
• Liao J K, Zulueta J J, Feng-Sheng Y, Peng H, Cote C G, Hassoun P M. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J CIin Invest 1995; 96: 2661–6
   PubMedGoogle Scholar
• Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz M A, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880–5
   PubMed Web of Science ®Google Scholar
• Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin 1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711–9
   PubMed Web of Science ®Google Scholar
• Mueck A O, Seeger H, Lippert T H. Fluvastatin reduces endothelin secretion of cultured human umbilical vein endothelial cells. Eur J Clin Pharmacol 1999; 55: 625–6
   PubMedGoogle Scholar
• Roullet J B, Xue H, Pappu A S, Roullet C, Holcomb S, McCarron D A. Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci USA 1993; 90: 11728–32
   PubMedGoogle Scholar
• Roullet J B, Xue H, Roullet C M, Fletcher W S, Cipolla M J, Harker C T, et al. Mevalonate availability affects human and rat resistance vessel function. J Clin Invest 1995; 96: 239–44
   PubMedGoogle Scholar
• Roullet J B, Xue H, Chapman J, McDougal P, Roullet C M, McCarron D A. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest 1996; 97: 2384–90
   PubMedGoogle Scholar
• Muller W A, Weigl S A, Deng X, Phillips D M. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993; 178: 449–60
   PubMed Web of Science ®Google Scholar
• Giachelli C M, Lombardi D, Johnson R J, Muny C E, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998; 152: 353–8
   PubMed Web of Science ®Google Scholar
• Rajavashisth T B, Andalibi A, Territo M C, Berliner J A, Navab M, Fogelman A M, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254–7
   PubMed Web of Science ®Google Scholar
• Warner S JC, Friedman G B, Libby P. Immune interferon inhibits proliferation and induces 2′-5′-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest 1989; 83: 1174–82
   PubMedGoogle Scholar
• Amento E P, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223–30
   PubMed Web of Science ®Google Scholar
• Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link. Lancet 1997; 349: 1391–2
   PubMed Web of Science ®Google Scholar
• Neumann F J, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation 1997; 95: 2387–94
   PubMed Web of Science ®Google Scholar
• Green F, Humphries S. Control of plasma fibrinogen levels. Bailliires CIin Haematol 1989; 2: 945–59
   PubMedGoogle Scholar
• Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938–44
   PubMed Web of Science ®Google Scholar
• Shiomi M, Ito T. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999; 126: 961–8
   PubMed Web of Science ®Google Scholar
• Padgett R C, Heistad D D, Mugge A, Armstrong M L, Piegors D J, Lopez J AG. Vascular responses to activated leukocytes after regression of atherosclerosis. Circ Res 1992; 70: 423–9
   PubMedGoogle Scholar
• Weber C, Erl W, Weber K SC, Weber P C. HMG-CoA reductase inhibitors decrease CDllb expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212–7
   PubMed Web of Science ®Google Scholar
• Bustos C, Hernandez-Presa H, Ortego M, Tunon J, Ortega L, Perez F, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057–64
   PubMed Web of Science ®Google Scholar
• Kimura M, Kurose I, Russell J, Granger D N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hyper-cholesterolemic rats. Arterioscler Thromb Vasc Biol 1997; 17: 1521–6
   PubMed Web of Science ®Google Scholar
• Duzendorfer S, Rothbucher D, Schratzberger P, Reinisch N, Kahler C M, Wiedermann C J. Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 1997; 81: 963–9
   PubMedGoogle Scholar
• Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996; 18: 669–75
   PubMed Web of Science ®Google Scholar
• Ikeda U, Shimada K. Statins and monocytes. Lancet 1999; 353: 2070
   PubMed Web of Science ®Google Scholar
• Bernini F, Scurati N, Bonfadini G, Fumagalli R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscl Thromb Vasc Biol 1995; 15: 1352–8
   PubMed Web of Science ®Google Scholar
• Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137(Suppl)S101–9
   PubMedGoogle Scholar
• Corsini A, Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 1996; 33: 56–62
   Google Scholar
• Corsini A, Raiteri M, Soma M R, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of drug intervention: focus on HMG-CoA reductase inhibitors. Am J Cardiol 1995; 76: 21A–8A
   PubMedGoogle Scholar
• Raiteri M, Arnaboldi L, McCeady P, Gelb M H, Verri D, Tagliabue C, et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997; 281: 1144–53
   PubMed Web of Science ®Google Scholar
• Scott W. Hydrophilicity and the differential pharmacology of pravastatin. Lipid management: pravastatin and the differential pharmacology of HMG-CoA reductase inhibitors, C Wood. Royal Society of Medicine Service, LondonUK 1989; 17–25, London Round Table Series no 16
   Google Scholar
• Komai T, Shigehara E, Tokui T, Koga T, Ishigami M, Kuroiwa C, et al. Carrier-mediated uptake of pravastatin by rat hepatocytes in primary culture. Biochem Pharmacol 1992; 43: 667–70
   PubMed Web of Science ®Google Scholar
• Bandoh T, Mitani H, Niihashi M, Bandoh T, Mitani H, Niihashi M, et al. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Clin Pharmacol 1996; 315: 37–42
   Google Scholar
• Igarashi M, Takeda Y, Mori S, Ishibashi N, Komatsu E, Takahashi K, et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYW6228 and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997; 120: 1172–8
   PubMed Web of Science ®Google Scholar
• Soma M R, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, et al. HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1993; 13: 571–8
   PubMed Web of Science ®Google Scholar
• Soma M R, Parolini C, Donetti E, Fumagalli R, Paoletti R. Inhibition of isoprenoids biosynthesis and arterial smooth muscle cell proliferation. J Cardiovasc Pharmacol 1995; 25: s20–4
   Google Scholar
• Bocan T MA, Mazur M J, Mueller S B, Brown E Q, Sliskovic D R, O'Brien P M, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994; 111: 127–42
   PubMedGoogle Scholar
• Gellman J, Ezekowitz M D, Sarembock I J, Azrin M A, Nochomowitz L E, Lerner E, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty. A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251–9
   PubMed Web of Science ®Google Scholar
• Zhu B Q, Sievers R E, Sun Y P, Isenberg W M, Parmley W W. Effect of lovastatin on suppression and regression of atherosclerosis in lipid-fed rabbits. J Cardiovasc Pharmacol 1992; 19: 246–55
   PubMedGoogle Scholar
• Dain J G, Fu E, Gorski J, Nicoletti J, Scallen T J. Biotrans-formation of fluvastatin sodium in humans. Drug Metab Dispos 1993; 21: 567–72
   PubMed Web of Science ®Google Scholar
• Tse F LS, Jaffe J M, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses of normal volunteers. J Clin Pharmacol 1992; 32: 630–8
   PubMed Web of Science ®Google Scholar
• Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori C R. Inhibitor of proliferation of arterial smooth muscle cells by fluvastatin. Lancet 1996; 348: 1584
   PubMed Web of Science ®Google Scholar
• Bochaton Piallant M L, Gabbiani F, Redard M, Desmouliere A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol 1995; 146: 1059–64
   PubMedGoogle Scholar
• Han D KM, Haudenschild C C, Hong M K, Tinkle B T, Leon M B, Liau G. Evidence for apoptosis in human atherogenesis and in rat vascular injury model. Am J Pathol 1995; 147: 267–77
   PubMed Web of Science ®Google Scholar
• Isner J M, Kearney M, Boartman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91: 2703–11
   PubMed Web of Science ®Google Scholar
• Kockx M M, Cambier B A, Bortier H E, De Meyer G R, Declercq S C, Van Cauwelaert P A, et al. Foam cell replication and smooth muscle cell apoptosis in human saphenous vein grafts. Histopathology 1994; 25: 365–71
   PubMed Web of Science ®Google Scholar
• Soma M R, Baetta R, De Renzis S, Mazzini G, Davegna C, Magrassi L, et al. In vitro and in vivo enhanced anti-tumor activity of carmustine (BCNU) by simvastatin, a hypo-cholesterolemic drug. Cancer Res 1995; 55: 597–602
   PubMed Web of Science ®Google Scholar
• Guijarro C, Blanco-Colio L M, Onego M, Alonso C, Ortiz A, Plaza J J, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490–500
   PubMed Web of Science ®Google Scholar
• Baetta R, Donetti E, Comparato C, Calore M, Rossi A, Teruzzi C, et al. In vitro and in vivo apoptosis by atorvastatin in stimulated smooth muscle cells. Phannacol Res 1997; 36: 115–21
   Google Scholar
• Serruys P W, Foley D P, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty, final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 1999; 20: 58–69
   PubMed Web of Science ®Google Scholar
• Weintraub W S, Boccuzzi S J, Klein J L, Kosinski A S, King S B, III, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994; 331: 1331–7
   PubMed Web of Science ®Google Scholar
• Bertrand M E, McFadden E P, Fruchart J C, van Belle E, Commeau P, Grollier G, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997; 30: 863–9
   PubMed Web of Science ®Google Scholar
• Falk E, Shah P K, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–71
   PubMed Web of Science ®Google Scholar
• Davies M J, Richardson P D, Woolf N, Katz D R, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377–81
   PubMedGoogle Scholar
• Fernandez-Ortiz A, Badimon J, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombo-genicity of atherosclerotic plaque components: implications for consequences of plaque rupture. Am J Coil Cardiol 1994; 23: 1562–9
   PubMed Web of Science ®Google Scholar
• Richardson P D, Davies M J, Born G VR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941–4
   PubMed Web of Science ®Google Scholar
• Dollery C M, McEwan J R, Henney A M. Matrix metallo-proteinases and cardiovascular disease. Circ Res 1995; 77: 863–8
   PubMed Web of Science ®Google Scholar
• Le Quan Sang K H, Levenson J, Megnien J L, Simon A, Devynck M A. Platelet cytosolic Caz+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759–64
   PubMedGoogle Scholar
• Osamah H, Mira R, Sorina S, Shlomo K, Michael A. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Phannacol 1997; 44: 77–83
   PubMed Web of Science ®Google Scholar
• Meade T W, Ruddock V, Stirling Y, Chakrabarti R, Miller G J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076–9
   PubMed Web of Science ®Google Scholar
• Dangas G, Badimon J J, Smith D A, Unger A H, Levine D, Shao J H, et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am CON Cardiol 1999; 33: 1294–304
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzha J, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 1999; 33: 1286–93
   PubMed Web of Science ®Google Scholar
• Essig M, Nguyen G, Prie D, Escoubet B, Sraer J D, Friedlander G. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Circ Res 1998; 83: 683–90
   PubMedGoogle Scholar
• Essig M, Vrtovsnik F, Nguyen G, Sraer J D, Friedlander G. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: role of geranylgeranylation and Rho proteins. J Am Soc Nephrol 1998; 9: 1377–1388
   PubMedGoogle Scholar
• Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1–8
   PubMed Web of Science ®Google Scholar
• Wilcox J N, Smith K M, Schwartz S M, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839–43
   PubMed Web of Science ®Google Scholar
• Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macro-phages: a novel mechanism of protection against atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 265–72
   PubMed Web of Science ®Google Scholar
• Koppensteiner R, Minar E, Ehringer H. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia. Atherosclerosis 1990; 83: 53–8
   PubMed Web of Science ®Google Scholar
• Beigel Y, Fuchs J, Snir M, Green P, Kurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fib-rinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol 1991; 31: 512–7
   PubMedGoogle Scholar
• Siperstein M D, Gyde A M, Moms H P. Loss of feedback control of hydroxymethylglutaryl coenzyme A reductase in hepatomas. Proc Natl Acad Sci USA 1971; 68: 315–7
   PubMed Web of Science ®Google Scholar
• Kandutsch A A, Hancock R L. Regulation of the rate of sterol synthesis and the level of P-hydroxy-P-methylglutaryl coenzyme A reductase activity in mouse liver and hepatomas. Cancer Res 1971; 31: 1396–401
   PubMed Web of Science ®Google Scholar
• Maltese W A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors. Neurology 1983; 33: 1294–9
   PubMed Web of Science ®Google Scholar
• Dunnington D J, Prichett W, Greig R. Stimulation of anchorage independent proliferation of human adreno-cortical carcinoma cells by inhibition of cholesterol biosynthesis. Biochem Biophys Res Commun 1989; 165: 219–25
   PubMedGoogle Scholar
• Bennis F, Favre G, Le Gaillard F, Soula G. Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocar-cinoma cell line A549. Int J Cancer 1993; 55: 640–5
   PubMed Web of Science ®Google Scholar
• Maltese W A. Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochim Biophys Res Commun 1984; 120: 454–60
   PubMedGoogle Scholar
• Soma M R, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R. Simvastatin, an inhibitor of cholesterol biosynthesis, shows synergistic effect with N, N′ - Bis (2-chloroethyl)-N-nitrosourea and p-interferon on human glioma cells. Cancer Res 1992; 52: 4348–5355
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck R D, Powles R L, Catovsky D, Millar J L. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997; 24: 533–7
   PubMed Web of Science ®Google Scholar
• Kiluchi T, Nagata Y, Abe T. In vitro and in vivo anti-proliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells. J Neurooncol 1997; 34: 233–9
   PubMedGoogle Scholar
• Choi J W, Jung S E. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells. J Pharmacol Exp Ther 1999; 289: 572–9
   PubMed Web of Science ®Google Scholar
• Maltese W A, Defendini R, Green R A, Sheridan K M, Donley D K. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Znvest 1985; 76: 1748–54
   PubMedGoogle Scholar
• Gibbs J B, Oliff A, Kohl N E. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 1994; 77: 175–8
   PubMed Web of Science ®Google Scholar
• Soma M R, Baetta R, De Renzis R, Mazzini G, Davegna C, Magrassi L, et al. In vivo enhanced antitumor activity of carmustine [N, N′-bis(2-chloroethyl)-N-nitrosourea] by simva-statin. Cancer Res 1995; 55: 597–602
   PubMed Web of Science ®Google Scholar
• Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem 1996; 66: 710–6
   PubMed Web of Science ®Google Scholar
• Jones K J, Couldwell W T, Hinton D R, Su Y, He S, Anker L, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994; 205: 1681–7
   PubMed Web of Science ®Google Scholar
• Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994; 199: 1209–15
   PubMed Web of Science ®Google Scholar
• Perez-Sala D, Collado-Escobar D, Mollinedo F. Intracellular alkalination suppresses lovastatin-induced apoptosis in HL60 cells through the inactivation of a pH-dependent indo-nuclease. J Biol Chem 1995; 270: 6235–42
   PubMed Web of Science ®Google Scholar
• Baetta R, Paoletti R, Fumagalli R, Soma M R. Mevalonate modulation of cell proliferation and apoptosis. Oncol Rep 1997; 4: 257–61
   Google Scholar
• Thibault A, Samid D, Tompkins A C, Figg W D, Cooper M R, Hohl R J, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483–91
   PubMed Web of Science ®Google Scholar
• Lamer J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998; 21: 579–83
   PubMedGoogle Scholar
• Fisher J E, Rogers M J, Halasy J M, Luckman S P, Hughes D E, Masarachia P J, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation. in vitro. Proc Nutl Acad Sci USA 1999; 96: 133–8
   PubMed Web of Science ®Google Scholar
• Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946–9
   PubMed Web of Science ®Google Scholar
• Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569–82
   PubMed Web of Science ®Google Scholar
• Aviram M, Dankner G, Cogan U, Hochgraf E, Brook J G. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism 1992; 41: 229–35
   PubMedGoogle Scholar
• La Ville A, Moshy R, Turner P R, Miller N E, Lewis B. Inhibition of cholesterol synthesis reduces low-density-lipoprotein apoprotein B production without decreasing very-low-density-lipoprotein apoprotein B synthesis in rabbits. BiochemJ 1984; 218: 321–3
   PubMedGoogle Scholar
• Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, et al. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology 1996; 87: 458–68
   PubMed Web of Science ®Google Scholar
• Sakai M, Kobori S, Matsumura T, Biwa T, Sato Y, Takemura T, et al. HMG-CoA reductase inhibitors suppress macro-phage growth induced by oxidized low density lipoprotein. Atherosclerosis 1997; 133: 51–9
   PubMed Web of Science ®Google Scholar
• Cignarella A, Brennhausen B, von Eckardstein A, Assmann G, Cullen P. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 1998; 18: 1322–9
   PubMed Web of Science ®Google Scholar
• Masaaki K, Kurose I, Russell J, Granger D N. Effect of fluvastatin on leukocyte-endothelial cell adhesion in hyper-cholesterolemic rats. Arterioscl Thromb Vasc Biol 1997; 17: 1521–6
   PubMedGoogle Scholar
• Kaesemeyer W H. Pravastatin sodium activates endothelial nitric oxide synthase independently of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234–41
   PubMed Web of Science ®Google Scholar
• Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells. Br J Pharmacol 1999; 126: 1205–13
   PubMed Web of Science ®Google Scholar
• Escobales N, Castro M, Altieri P I, Sanabria P. Simvastatin releases Ca2+ from thapsigargin-sensitive pool and inhibits InsP3-dependent Ca2+ mobilization in vascular smooth muscle cells. J Cardiovasc Pharmacol 1996; 27: 383–91
   PubMedGoogle Scholar